EMA Authorised: Crysvita (burosumab) — Kyowa Kirin Holdings B.V.

View source ↗

Summary

EU authorization for Crysvita (burosumab) for familial hypophosphatemia, X-linked dominant hypophosphatemic rickets, and osteomalacia, granted to Kyowa Kirin Ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypophosphatemia
• Hypophosphatemic Rickets X-linked Dominant
• Osteomalacia

Drugs mentioned

• Crysvita (burosumab)

Snippet

Status: Authorised. Therapeutic area: Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia. MAH: Kyowa Kirin Holdings B.V.. Decision date: 29/05/2026. Orphan medicine